<DOC>
	<DOCNO>NCT02250222</DOCNO>
	<brief_summary>Ligand Pharmaceuticals Incorporated develop LGD-6972 , novel , orally-bioavailable addition diet exercise improve glycemic control adult type 2 diabetes mellitus . The mechanism action LGD-6972 reduce excess liver glucose production characteristic type 2 diabetes mellitus major contributor hyperglycemia . This clinical trial evaluate safety tolerability escalate dos LGD-6972 administer daily 2 week healthy subject subject type 2 diabetes mellitus .</brief_summary>
	<brief_title>Safety Tolerability Study Oral LGD-6972 Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , sequential , multiple oral dose study conduct normoglycemic healthy subject ( NHS ) ( Part 1 ) subject type 2 diabetes mellitus ( T2DM ) treat monotherapy metformin ( stable dose randomization ) along diet exercise ( Part 2 ) . Subjects T2DM stable dose metformin meet entry criterion may enrol study discretion Investigator , must undergo stabilization period least 12 week determine eligibility study . In Part 1 , single group healthy subject dose repeated oral dos 15 mg LGD-6972 placebo daily ( QD ) 14 day . In Part 2 , maximum 3 group subject T2DM dose 3 sequential , increase dos LGD-6972 ( 5 mg , 10 mg 15 mg ) placebo QD 14 day .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>INCLUSION CRITERIA : Part 1 1 . Healthy , adult man woman , 21 65 year age . If subject woman , must surgically sterile naturally postmenopausal consider enrollment . 2 . Willing able provide write informed consent . 3 . Not diabetic fast plasma glucose ( FPG ) 70 mg/dL 105 mg/dL , inclusive . 4 . Good health significant concomitant pathology base medical history , physical examination , electrocardiogram ( ECG ) , routine laboratory test ( chemistry , hematology , lipid profile , international normalize ratio , urinalysis ) , vital sign . Part 2 1 . Healthy , adult man woman , 21 65 year age . If subject woman , must surgically sterile naturally postmenopausal consider enrollment . 2 . Willing able provide write informed consent . 3 . Has T2DM accord American Diabetes Association criterion . 4 . Currently stable metformin therapy ( unchanged dose great equal 12 week prior screen ) . At discretion investigator , subject drug naïve whose metformin dose stable least 12 week screen , may start metformin metformin dose stabilize . Following 12 week stable metformin , may undergo screen include assessment HbA1c FPG ( inclusion criterion 5 6 ) . 5 . Has HbA1c level 6.5 % 10.5 % screening . One retest permit . 6 . Venous FPG 125 mg/dL 260 mg/dL screen either Day 1 venous FPG Day 1 capillary blood glucose ( CBG ) 115 mg/dL 260 mg/dL . One retest permit . 7 . Has body mass index 20 45 kg/m2 , inclusive . EXCLUSION CRITERIA : Part 1 1 . Has recent history drug and/or alcohol abuse . 2 . Unwilling comply tobacco , nicotine , alcohol , caffeine restriction specify protocol . 3 . Unwilling comply restriction strenuous exercise specify protocol . 4 . Has history clinically significant cardiovascular , pulmonary , renal , endocrine , hepatic , neurologic , psychiatric , immunologic , hematologic , gastrointestinal ( include pancreatitis ) , metabolic disease require medical treatment medical problem pose increase risk study may compromise integrity study data . 5 . Has liver transaminase level ( aspartate transaminase [ AST ] alanine transaminase [ ALT ] ) &gt; 10 % upper limit normal ( ULN ) , creatine kinase ( CK ) level &gt; 2 × ULN screen admission clinic ( Day 1 ) . 6 . Has plasma triglyceride level &gt; 400 mg/dL . If triglyceride level 400 mg/dL 500 mg/dL . 7 . Has recent history uncontrolled high blood pressure systolic blood pressure &lt; 90 mmHg &gt; 140 mmHg diastolic blood pressure &lt; 60 mmHg &gt; 90 mmHg screening . 8 . Is take prescription nonprescription drug , vitamin , herbal , dietary supplement , within 14 day 5 halflives ( whichever longer ) prior first dose study drug , unwilling refrain take medication last protocolspecified blood sample . The use acetaminophen , exceed total daily dose 1 g , permit 24 hour prior admission investigational site prohibit last protocolspecified blood sample . The use stable hormone replacement medication woman , topical steroid , stable thyroid medication permit . Part 2 1 . Has history hypoglycemic unawareness recurrent hypoglycemia require assistance . 2 . Has liver transaminase level ( AST ALT ) &gt; 10 % × ULN , CK level &gt; 1.5 × ULN screen admission clinic ( Day 1 ) . 3 . Has history clinically significant cardiovascular , pulmonary , renal , endocrine ( T2DM ) , hepatic , neurologic , psychiatric , immunologic , hematologic , gastrointestinal ( include pancreatitis ) , metabolic disease require medical treatment medical problem pose increase risk study may compromise integrity study data . 4 . Has recent history uncontrolled high blood pressure systolic blood pressure &lt; 90 mmHg &gt; 140 mmHg diastolic blood pressure &lt; 60 mmHg &gt; 90 mmHg screening . One retest blood pressure within 24 hour permissible discretion Investigator . Therapy hypertension ( beta blocker exclude ) stable least one month prior screen permit . At Investigator 's discretion , one antihypertensive medication ( angiotensin convert enzyme inhibitor , angiotensin receptor blocker , hydrochlorothiazide , dihydropyridine calciumchannel blocker ) may initiate , dosage current antihypertensive medication titrate , subject blood pressure slightly eligibility criterion screening . After least 4 week stable blood pressure treatment , subject 's blood pressure decrease within 140/90 mmHg limit , subject fully reassess eligibility . 5 . Has receive insulin 6 consecutive day within 6 month prior screen receive insulin within 3 month prior screen . 6 . Has treat peroxisome proliferatoractivated receptor gamma agonist , incretin therapy , amylin mimetics , sodiumglucose link transporter2 inhibitor therapy within 12 week prior screen ; treatment diabetic medication ( exclude metformin ) within 3 week prior screen . 7 . Is take concomitant medication . At least 3 month stable therapy thyroid replacement hypercholesterolemia ( gemfibrozil , Welchol , cholestyramine permit ) least 4 week stable hypertension medication ( describe ) low dose aspirin permit .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>